Analysts Expect Adamis Pharmaceuticals Corp (ADMP) Will Announce Earnings of -$0.19 Per Share

Share on StockTwits

Wall Street analysts expect Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to report earnings per share (EPS) of ($0.19) for the current quarter, Zacks reports. Two analysts have issued estimates for Adamis Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.22) and the highest is ($0.16). Adamis Pharmaceuticals posted earnings per share of ($0.24) during the same quarter last year, which indicates a positive year-over-year growth rate of 20.8%. The business is scheduled to issue its next earnings results on Thursday, March 21st.

According to Zacks, analysts expect that Adamis Pharmaceuticals will report full-year earnings of ($0.90) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.86). For the next financial year, analysts forecast that the company will post earnings of ($0.56) per share, with EPS estimates ranging from ($0.69) to ($0.43). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Adamis Pharmaceuticals.

Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings results on Friday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). Adamis Pharmaceuticals had a negative return on equity of 87.64% and a negative net margin of 248.43%. The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $5.39 million.

Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Adamis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research note on Friday. HC Wainwright set a $7.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 13th. B. Riley cut Adamis Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $7.50 to $2.50 in a research note on Monday, November 12th. Finally, Maxim Group set a $10.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 7th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $5.85.

ADMP stock opened at $2.54 on Monday. Adamis Pharmaceuticals has a twelve month low of $2.01 and a twelve month high of $5.10. The company has a market cap of $118.23 million, a PE ratio of -2.82 and a beta of 1.06.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. First Manhattan Co. bought a new position in Adamis Pharmaceuticals during the third quarter worth $11,967,000. Vanguard Group Inc lifted its stake in Adamis Pharmaceuticals by 27.1% in the third quarter. Vanguard Group Inc now owns 1,637,513 shares of the specialty pharmaceutical company’s stock valued at $5,731,000 after buying an additional 348,645 shares during the last quarter. Vanguard Group Inc. lifted its stake in Adamis Pharmaceuticals by 27.1% in the third quarter. Vanguard Group Inc. now owns 1,637,513 shares of the specialty pharmaceutical company’s stock valued at $5,731,000 after buying an additional 348,645 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Adamis Pharmaceuticals by 71.4% in the third quarter. DekaBank Deutsche Girozentrale now owns 1,200,000 shares of the specialty pharmaceutical company’s stock valued at $3,360,000 after buying an additional 500,000 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in Adamis Pharmaceuticals by 203.2% in the third quarter. BlackRock Inc. now owns 889,440 shares of the specialty pharmaceutical company’s stock valued at $3,113,000 after buying an additional 596,112 shares during the last quarter. Hedge funds and other institutional investors own 22.37% of the company’s stock.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Read More: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply